Qureight has appointed Patrick Driscoll as the company’s Chief Financial Officer, strengthening the company’s financial and operational capabilities.

As we step into 2025, we take a moment to reflect on the past few months, which has been a busy and exciting period for Qureight. With new team members, Christmas parties, securing funding, industry recognition, and new partnerships, we’re making progress in our mission to transform clinical trials through deep-learning imaging.

Qureight Ltd and Vicore Pharma today announce the implementation of Qureight’s Core Imaging Platform within the global Phase 2b ASPIRE trial investigating buloxibutid in patients with idiopathic pulmonary fibrosis (IPF).

The partnership will commence with the ongoing MIST study, a Phase 2b clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF).

This milestone highlights our commitment to safeguarding sensitive data and establishing greater trust within our partners and stakeholder community.

‍Techbio company Qureight has appointed Dr Simon Walsh to the role of Chief Scientific Officer (CSO). This significant strategic appointment will deliver expert clinical oversight and technical support to drive Qureight's research and development pipeline.

Qureight has announced a partnership with King Faisal Specialist Hospital and Research Centre for Innovative Lung Transplant Research Pilot

Qureight has announced the appointment of Javier Alvarez Valle to the Qureight Scientific Advisory Board.

Qureight has announced the appointment of Claus Torp Jensen to the role of Chairperson of the Board.

Qureight and Vicore Pharma publish results indicating that patients with earlier stage idiopathic pulmonary fibrosis (IPF) are more likely to have improvement in lung function in response to treatment with Vicore’s novel angiotensin II type 2 agonist, C21.

Cambridge-based data analytics company Qureight has entered into a multi-year collaboration with the biopharmaceutical company AstraZeneca.

The Qureight team is delighted to welcome Dr Pilar Rivera-Ortega on to our Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF).

Qureight is excited to be collaborating with the patientMpower team on a project to uncover new prognostic markers in interstitial lung disease (ILD).

Dr Muhunthan Thillai CEO said "We are really excited that Dr Fernandez has joined us to assist the company with our data strategy as we expand operations. Xose brings over 25 years’ experience...

Qureight has met the requirements to use our quality management system for the design of medical devices. We are pleased as it shows our dedication to maintaining a high quality QMS as we continue to develop our platform.